The risk of adverse health outcomes in achondroplasia, from cardiovascular diseases, pain, poor function, excess weight, and sleep apnea is unclear. This multicenter retrospective natural history study works as a patient registry and was conducted in the US to understand medical and surgical practices in achondroplasia.

On June 25, 2021, the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency, EMA, recommended the marketing authorisation of Voxzogo (trade name of vosoritide) in the European Union (EU)...

This recent study by Dr. Wiktoria Wrobel (Medical University of Lublin, Poland) brings together the different pharmacological treatments for achondroplasia, both current and potential, highlighting the advantages and disadvantages of each, making it a great comprehensive review.

A paper1 on a Quality of Life research study conducted by Kathryn M. Pfeifer et al aims to develop a better understanding of the experiences of parents of children with achondroplasia.

What is still to be understood on how gait in children with achondroplasia is altered compared to average height children. 

A recently published article by Julie Hoover-Fong et al.1 seeks to synthesize the current knowledge base about the nature, incidence, chronology, and the interrelationships of achondroplasia-related comorbidities across the lifespan.